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Bacterial burdenBackground: Tuberculous pericarditis is considered to be a paucibacillary process; the large pericardial ﬂuid
accumulation is attributed to an inﬂammatory response to tuberculoproteins. Mortality rates are high.We inves-
tigated the role of clinical andmicrobial factors predictive of tuberculous pericarditismortality using the artiﬁcial
intelligence algorithm termed classiﬁcation and regression tree (CART) analysis.
Methods: Patients were prospectively enrolled and followed in the Investigation of theManagement of Pericardi-
tis (IMPI) registry. Clinical and laboratory data of 70 patients with conﬁrmed tuberculous pericarditis, including
time-to-positive (TTP) cultures from pericardial ﬂuid, were extracted and analyzed formortality outcomes using
CART. TTP was translated to log10 colony forming units (CFUs) per mL, and compared to that obtained from
sputum in some of our patients.
Findings: Seventy patients with proven tuberculous pericarditis were enrolled. The median patient age was 35
(range: 20–71) years. The median, follow up was for 11.97 (range: 0·03–74.73) months. The median TTP for
pericardial ﬂuid cultures was 22 (range: 4–58) days or 3.91(range: 0·5–8·96) log10CFU/mL, which overlapped
with the range of 3.24–7.42 log10CFU/mL encountered in sputum, amulti-bacillary disease. The overall mortality
rate was 1.43 per 100 person-months. CART identiﬁed follow-up duration of 5·23 months on directly observed
therapy, a CD4+ count of ≤199.5/mL, and TTP ≤ 14 days (bacillary load ≥ 5.53 log10 CFU/mL) as predictive of
mortality. TTP interacted with follow-up duration in a non-linear fashion.
Interpretation: Patients with culture conﬁrmed tuberculous pericarditis have a high bacillary burden, and this
bacterial burden drivesmortality. Thus proven tuberculosis pericarditis is not a paucibacillary disease. Moreover,
the severe immunosuppression suggests limited inﬂammation. There is a need for the design of a highly
bactericidal regimen for this condition.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculous (TB) pericarditis accounts for 50–70% of pericardial
disease in Africa (Mayosi et al., 2005, 2006, 2008). Mortality rates
range between 17 and 60% (Mayosi et al., 2008; Pusch et al., 2014;
Shaw et al., 2010). The Investigation of theManagement of Pericarditis
(IMPI) registry, a prospective observational study, revealed a case fatal-
ity rate of 26% within 6-months of diagnosis (Mayosi et al., 2008). Sev-
eral host-factors were independent predictors of this early mortality,ses Research and Experimental
Medical Center, 3434 Live Oak
. Gumbo).
. This is an open access article underincluding the presence of HIV infection, increasing age, and concurrent
pulmonary TB (Mayosi et al., 2008). However, these patients were
followed up for only 6months, and a deﬁnitive TB pericarditis diagnosis
was conﬁrmed in only 7% of patients. Thus, factors predictive of long-
term outcomes in patients with proven TB pericarditis still need to be
identiﬁed. Here, we identiﬁed factors predictive of long-term outcome
using classiﬁcation and regression tree (CART) analyses. We used
CART becausewe did not want to use amodel that pre-speciﬁed the im-
portant potential predictors. Instead we wanted a distribution- and
assumption-free method to identify the predictors in the context of all
potential clinical and laboratory factors. We also wanted to rank the
predictors, in order to allow clinical decisionmaking as to which factors
to modify ﬁrst to have the largest impact on reducing TB pericarditis
mortality.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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large pericardial ﬂuid accumulation is attributed to an inﬂammatory
response caused by a few tuberculoproteins (Cherian, 2004; Fowler,
1991). For that reason, the same regimen and doses used for pulmonary
TB, and for the same duration, are administered to patients with extra-
pulmonary TB including TB pericarditis (Mayosi et al., 2005, 2006,
2008, 2002; Pusch et al., 2014; Shaw et al., 2010; Cherian, 2004;
Fowler, 1991). However, the baseline bacillary burden or temporal
changes in bacillary loadwith therapy are yet to be rigorously quantiﬁed.
These microbial factors are known to be important determinants of out-
come in patients on the same type of standard therapy for pulmonary TB
(Bowness et al., 2015; Diacon et al., 2010; Chigutsa et al., 2013, 2015).
Here,weused the IMPI registry to investigatemicrobial, clinical, echocar-
diography and hemodynamic factors as possible predictors of long term
death. Uniquely, we had an access to quantitativemicrobiology informa-
tion based on liquid culture,which is known to better capture larger pop-
ulations ofMycobacterium tuberculosis (Mtb) than solid agar techniques.
2. Methods
2.1. Study Setting and Study Design
The goal of the IMPI registry is to improve the outcomes of patients
with TB pericarditis in resource-limited settings by improving access to
clinical decision-making information (Mayosi et al., 2006). IMPI
prospectively recruits patients with presumptive TB pericarditis from
clinics across several African countries, collects and records observational
data and then systematically analyzes these data to answer speciﬁc ques-
tions.We used the registry to investigate the role of severalmicrobial and
clinical factors as predictors of early and late mortality in patients with
microbiologically proven TB pericarditis. We speciﬁcally focused on pa-
tients treated at Groote Schuur Hospital, a tertiary and teaching facility
in Cape Town, South Africa, in order to control for uniformity of care, es-
pecially microbiology laboratory use and access. We examined study pa-
tients who had been treated at Groote Schuur Hospital between January
2006 and December 2010, and followed-up until January 1st 2012.
All patients received standard ﬁrst-line anti-TB therapy recom-
mended by the South African National Tuberculosis Program. Patients
with prior TB history or retreatment were put on a longer regimen of
the same ﬁrst-line anti-TB drugs supplemented with streptomycin in
the intensive phase. HIV-infected patients were treated with anti-
retroviral drugs in line with local practice guidelines at the time
(National Department of Health, 2004). (http://southafrica.usembassy.
gov/media/2004-doh-art-guidelines.pdf) Progression of HIV and
response to antiretroviral therapy was monitored using CD4+ T cell
counts.
2.2. Deﬁnition of Terms
Pericardial constriction was deﬁned using clinical and echocardio-
graphic criteria described in the IMPI trial (Mayosi et al., 2014). The
vital status of the patient (i.e. whether the patient was alive or dead by
the censure date)was based on death certiﬁcate copies from themedical
records and use of the eKapa and Clinicom databases, the Department of
Home Affairs death records database and via verbal autopsy from family
members. January 1st 2012 was set as the censure date.
2.3. Inclusion and Exclusion Criteria
The inclusion criteria for the IMPI registry is pericardial effusion con-
ﬁrmed via echocardiography in a patient with suspected TB (Mayosi
et al., 2006). Patients with a presumptive diagnosis of tuberculous peri-
carditis andmet eligibility for the IMPI registry also met study inclusion
criteria. However, we excluded patients who did not have proven or
deﬁnite tuberculous pericarditis for this sub-study of the IMPI registry.
Additionally, only those patients who had pericardiocentesis withinone week of diagnosis were included in this study. We included only
patientswhohad been treated for 3 days or lesswith anti-TB antibiotics.
2.4. Modeling Bacillary Burden in Pericardial Fluid and Sputum
The standard laboratory measure of Mtb burden is colony-forming
units per milliliter (CFU/mL); in sputum a smear grade is also used in
clinical practice (Bowness et al., 2015; Diacon et al., 2010; Chigutsa
et al., 2013, 2015; Epstein et al., 1998; Pfyffer et al., 1997; Giampaglia
et al., 2007; Kolibab et al., 2014; Davies, 2010). Unfortunately, CFU/mL
determinations are labor-intensive, time-consuming, require a biosafe-
ty level 3 facility, and at least 3 weeks of incubation. On the other hand,
the mycobacterium growth indicator tube (MGIT) [Becton Dickinson
Microbiology Systems, NJ, USA] liquid media system has become the
standard inMtb cultures for clinical specimens in South Africa (Diacon
et al., 2010; Chigutsa et al., 2013, 2015). The MGIT reports a culture's
time-to-positivity (TTP); the higher the bacillary load, the shorter the
TTP (Epstein et al., 1998; Pfyffer et al., 1997; Giampaglia et al., 2007;
Kolibab et al., 2014; Davies, 2010). Since TTP is highly correlated with
CFU/mL, we utilized the TTP of pericardial cultures from 70 samples
from the IMPI patients and a comparable randomly selected sputum
samples from 18 patients with conﬁrmed pulmonary TB from the
South African TB reference laboratory in the Gauteng province, South
Africa, to calculate the log10 CFU/mL. In the MGIT, a specimen without
growth in over 60 days of incubation was considered negative for Mtb
infection. Ziehl–Neelsen stainingwas used routinely to conﬁrm positive
MGIT results at Groote Schuur Hospital.
We used two approaches to translate TTP (in days) to CFU/mL, based
on methods published in the literature (Bowness et al., 2015; Chigutsa
et al., 2013, 2015; Davies, 2010). The ﬁrst method is more conservative
because it does not account for therapy received, has an r2 of 0.998, and
employs the following formula:
log10 CFU=mL ¼ 2:6818e−0:046TTP: ð1Þ
The secondmethod is derived from theGompertzmodel andwas re-
cently used by Bowness et al. (2015). Thismethod accounts for bacterial
decline during the ﬁrst week of therapy. The formula is as follows:
log10 CFU=mL ¼
TTP− 562:318e−0:789e−0:195t
 
−64:111e1:002e−0:248t
; ð2Þ
where t denotes the days on therapy. The ﬁnal pericardial ﬂuid CFU/mL
was adjusted for dilution made during sample preparation for each
patient. Data extracted from the patients' notes did not indicate the
number of days the patients was on therapy prior to pericardiocentesis.
We assumed that most patients have the initial pericardiocentesis after
receiving at least three days' worth of antibiotics (empirical anti-TB
therapy is recommended for suspected pericardial TB by the national
program). Given that we had excluded patients who received more
than 3 days of therapy, we used the t = 3 for baseline log10CFU using
this method.
2.5. Classiﬁcation and Regression Tree Analysis
CART analysis is a machine-learningmethod that is distribution-free
and can be used to assist in decision-making in the clinic (Breiman et al.,
1984; Steinberg and Colla, 1995). CART analyses reveal trees that rank
the important selected predictors and are akin to decision-making
trees. Patients' demographic and clinical information including age,
gender, HIV-infection, CD4+ T cell counts, receipt of anti-retroviral
therapy, and history of active TBwere examined using CART. Additional
variables such asmeasures of hemodynamic stability (initial systolic, di-
astolic blood pressure and mean arterial pressure), heart rate, presence
of pericardial constriction, receipt of pericardiectomy, and TTP derived
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dependent variables (such as measures of HIV-infection related immu-
nosuppression) are highly correlated, and interact with both host and
pathogen factors in a nonlinear fashion. This would make it difﬁcult to
separate them out using standard multivariate logistic or linear regres-
sion models (Breiman et al., 1984; Steinberg and Colla, 1995; Shadish
et al., 2001; Breiman, 2001). Our approach to using CART for variable
selection, and threshold identiﬁcation of diseases outcomes in patients
has been well described in the past (Pasipanodya et al., 2013; Gumbo
et al., 2014; Jain et al., 2013; Pasipanodya and Gumbo, 2011). The
main outcome we examined was mortality on follow-up. Priors were
set to equal (i.e., all categories had equal probability assignment), with
no penalty sets for misclassiﬁcation. GINI methods were used for build-
ing trees together with V-fold cross-validation of each tree (Steinberg
and Colla, 1995; Breiman, 2001). CART analyses were performed using
the Salford Predictive Miner System software (San Diego, CA).
2.6. Standard Statistical Analysis
After CART use, standard frequentist inference analyses were
performed to estimate associations and parameter estimates of time-
to-death for comparison with existing literature. Cox proportional
hazard models that used variables and thresholds identiﬁed by the
CART analysis were utilized. Proportional hazard assumptions were
examined by examining plots as residuals (Shadish et al., 2001). All
analyses were two-sidedwith alpha at 0.05 performed with STATA ver-
sion 12, College Station, Texas.
3. Results
The laboratory and clinical characteristics of patients at enrolment
are shown in Table 1. Thesewere the same in patients with TB conﬁned
to pericardium compared to those with TB pericarditis and evidence of
TB in another body organ; the only difference was that antiretrovirals
were used more commonly in the latter group (4/6 patients) compared
to the former (5/38). Cardiac tamponade, either at presentation or in the
course of TB therapy, was observed in 3/70 (4%) patients. The CD4+ TTable 1
Comparison of clinical and laboratory characteristics of 58 patients with exclusive tuberculous
Variable Total (n = 70) Tub
Sex Female 22 (31)
Male 48 (69)
Age (years) Median (IQR) 35 (30–48)
Previous TBa No 53 (87)
Yes 8 (13)
HIV-test result Negative/Not Done 23 (33)
Positive 47 (67)
Pericardial calciﬁcationa No 16 (70)
Yes 7 (30)
Pericardial Constriction None 62 (89)
Yes 8 (11)
Pericardiectomy No 67 (96)
Yes 3 (4)
Comorbid conditions None 56 (80)
Some 14 (20)
Baseline NYHAa II 9 (15)
III 30 (50)
IV 21 (35)
Oral steroidsa None 17 (44)
Some 22 (56)
Antiretroviral therapy None 35 (80)
Some 9 (20)
Adenine deaminase level (IU/L) Median (IQR) 74.7 (53–107.6)
Globulin (g/L) Median (IQR) 53.5 (47–58)
CD4+ counts (per mL) Median (IQR) 116 (61·5–266)
a Total does not add to 70 because data for some patient categories were missing; IQR — Int
statistically signiﬁcant difference.cell counts for 53/70 (80%) of patients shown Fig. 1 reﬂect overall im-
munosuppression in study patients. The median follow-up duration
was 11.97 (range: 0·03–74.73) months. Of the 70 patients, 16 (23%)
died during the 75-month follow-up period. The overall mortality rate
was 1.43 per 100 person-month follow-up.
To put the pericardialMtb burden into context, 18 sputum samples
from 18 randomly chosen patients with pulmonary TB, based on a
South African reference laboratory, were compared to 70 pericardial
ﬂuid samples from IMPI patients. The pulmonary TB patients had a me-
dian age of 40 (range 22–44) years compared to 35 (range 30–71) years
of thosewith pericardial TB (p=0.600). Fig. 2A shows the bacillary bur-
den in terms of TTP, while Fig. 2B shows the bacillary burden as
log10CFU/mL based on the more conservative formula. The median
TTP for pericardial sampleswas 22 (range 4 to 58) days and that for spu-
tumwas 12 days (p b 0.001). Fig. 2B shows that even though overall ba-
cillary burden was signiﬁcantly higher in sputum samples (mean
difference 2.22 ± 0.34 log10CFU, p b 0.001), the mean baseline bacillary
load for pericardial ﬂuid samples (3.86 ± 0.21 log10CFU), was substan-
tial and inconsistent with a paucibacillary process. The baseline CFU/mL
in pericardial ﬂuid is higher (median = 8.55 log10CFU/mL) using a dif-
ferent but more stringent modeling approach (Fig. 3).
CART models identiﬁed the most important predictors of mortality
as duration of therapy or follow-up (importance score = 100%),
CD4+ T cell counts (score = 47%), TTP (score = 38%), and age
(score = 21%). The identiﬁed thresholds (which partitioned patients
to homogenous groups with similar mortality risk) shown in Table 2,
were a follow-up or therapy duration of 5.23 months, a CD4+ T cell
count of 199·5, and a TTP ≤14 days. CART identiﬁed an interaction be-
tween TTP and follow-up duration; patients with TTP ≤14 days (i.e.
high bacillary loads) had signiﬁcantly higher mortality rates earlier
than 5.3 months. The meaning of an interaction in machine learning is
that of a predictor modifying another predictor's effect on the outcome
(i.e., mortality in this case). A TTP of ≤14 days translates to
≥5.65 log10CFU/mL. Notably, measures of hemodynamic instability,
heart rate, use of oral steroids, adenosine deaminase level or gender
were not ranked. HIV-infection status or use of anti-retrovirus medica-
tions was also not ranked. The best CART model receiver-operatingpericarditis and 12 patients who also had tuberculosis elsewhere.
erculosis elsewhere (n = 12) Exclusive TB pericarditis (n = 58) p-Value
5 (42) 17 (29) 0.401
7 (58) 41 (71)
31.5 (29·5–39·5) 35·5 (29–50) 0.663
10 (91) 43 (86) 0.662
1 (9) 7 (12)
4 (33) 19 (33) 1.000
8 (67) 39 (67)
3 (100) 13 (65) 0.526
0 7 (35)
12 (100) 50 (86) 0·340
0 8 (14)
12 (100) 55 (95) 0.590
0 3 (5)
9 (75) 47 (87) 0.372
3 (25) 11 (13)
1 (9) 8 (16) 0.674
5 (45) 25 (51)
5 (46) 16 (33)
3 (38) 14 (45) 1.000
5 (62) 17 (55)
2 (33) 33 (87) 0.011
4 (67) 5 (13)
67 (52–85) 76 (51–110) 0.909
53 (43–54) 56 (51–60) 0.416
111 (22–254) 107 (15–254) 0.204
erquartile range: NYHA — New York Heart Association functional classiﬁcation; Italics—
Fig. 2. Mycobacterium tuberculosis burden in pericardial ﬂuid compared to sputum The
baseline bacillary load in 18 sputa produced by 18 different patients and in 70 pericardial
ﬂuid samples also from 70 separate patients is shown. The box and whisker plots in both
panel Fig. 2A andB showall data points,while the lines denote themedian, interquartile as
well as theminimum andmaximumvalues. The p-values are for both theMann–Whitney
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This means that the probability of obtaining similar results with an
independent dataset is at least 68%.
CART output was examined in standard logistic regression, with re-
sults shown in Table 2. Among patients with Mtb N 5.53 log10CFU/mL
mortality incidencewas 6/197·7 person-months and themortality inci-
dence rate was 0·03 compared to 10/920 person-months andmortality
rate of 0·01 (Fig. 4). The incidence rate difference was −0.02 (95%
−0.04 to 0.01), p = 0.031. Multivariable analysis based on time-to-
death as an outcome on follow-up in a Cox proportional hazards
model revealed a hazards-ratio of 3.57 (95% conﬁdence interval:
1.27–10·00; p = 0.016) in patients N29 years and 2.91 (95% conﬁ-
dence interval: 1.03–8·21; p = 0.044) in patients with pericardial
Mtb N5.53 log10CFU/mL.
4. Discussion
There were threemain ﬁndings in this study. First, mortality rates in
proven TB pericarditis were high. The fact that the overwhelming
majority of deaths in this cohort occurred during directly observed ther-
apy is troubling, and the timing of 5.3months suggests that this is more
a failure of therapy rather than death from chronic complications such
as constriction. Since all patients were on directly observed therapy,
failure in this case may have had little to do with poor adherence.
There are two possible explanations for this failure of therapy, both
pharmacokinetic/pharmacodynamic (PK/PD) in nature (Shenje et al.,
2015; Pasipanodya and Gumbo, 2011). First, it is most likely that there
are inadequate antibiotic concentrations in TB pericardial ﬂuid, espe-
cially of the primary sterilizing effect drugs rifampin and pyrazinamide,
due to poor penetration, as we have shown elsewhere (Shenje et al.,
2015). There is now sufﬁcient hollow ﬁber and prospective clinical
studies evidence to show that both the bactericidal activities and the
sterilizing effect of antibiotics in TB is driven by high peak concentration
and the area under the concentration-time curve of each drug, and
that evolution-mandated pharmacokinetic variability drives many
patients on recommended doses to not achieve optimal peak and
area under the concentration–time curve concentrations (Shenje et al.,
2015; Pasipanodya and Gumbo, 2011; Gumbo et al., 2015;
Pasipanodya et al., 2013; Srivastava et al., 2011). Secondly, CART identi-
ﬁed a CD4+T cell count ≤199.5 as amajor predictor. This happens to be
the exact CD4+ T cell count cut-off point that deﬁnes severeFig. 3. Mycobacterium tuberculosis burden using the less conservative method. This less
conservative method by Bowness et al., which takes into account days of therapy, leads
to higher bacterial burdens that average about 8.55 log10CFU/mL in pericardial ﬂuid.
test to compare median values and the Kolmogorov–Smirnov test to examine and
compare the variability and shape of the distributions between the two samples. Panel A
shows the bacillary burden in time-to-positive (TTP) cultures in days. Panel B shows the
bacillary burden in Log10 colony forming Units per mL (CFU/mL).
Fig. 1. CD4+T cell count distribution in patientswith proven tuberculous pericarditis. The
ﬁgure shows the CD4+ T cell count distribution in patients with and without conﬁrmed
HIV and those with HIV test result missing demonstrating remarkably low CD4+ T cell
counts in all study patients. CD4+ T cell counts data were missing in 17/70 (20%) of pa-
tients including 4/5 (80%) of patients with missing HIV test result. Baseline CD4+ T cell
counts were signiﬁcantly higher in HIV negative patients than positive, p b 0·001. The
median values are shown in ﬁgure.
Table 2
Mortality proportions for CART identiﬁed predictors of mortality.
Variablea Died n = 16 (%) Alive n = 54 (%) p-Valueb Unadjusted OR (95% CI)
CD4+ T cell counts ≤199.5/mL 11 (30) 26 (70) 0.266 Ref
N199.50 2 (11) 17 (89) 0.28 (0.05, 1.41)
Missing 3 (21) 11 (79) 0.64 (0.15, 2.77)
Age ≤29 7 (41) 10 (59) 0.039 Ref
N29 9 (17) 44 (83) 0.29 (0.09, 0.97)
Follow-up ≤157 days 11 (58) 8 (42) b0.001 Ref
N157 days 5 (10) 46 (90) 0.08 (0.02, 0.29)
Bacillary burden
Mtb log10 CFU/mL ≤5.53 10 (18) 46 (82) 0.046 3.45 (0.98, 12.17)
N5.53 6 (43) 8 (57) Ref
Time to positivity ≤14 days 6 (43) 8 (57) Ref
N14 days 10 (18) 46 (82) 0.046 0.29 (0.08, 1.02)
a Row (%) shown.
b Chi-square tests; computed odds ratio (OR) univariate logistic regression; CFU-Colony forming unit; Italics — statistically signiﬁcant difference.
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agent (that is why it exists), and these patients would have been
deprived of that advantage.
The second main ﬁnding is that proven TB pericarditis may not
be a paucibacillary disease as previously proposed; (Theron et al.,
2014) indeed patients who died had pericardial bacterial burden
of N5.53 log10CFU/mL. This result is with the more conservative
method to correlate TTP to CFU/mL of pericardial ﬂuid. Use of the less
conservative method revealed bacterial burdens in Fig. 3, much higher
than even those in sputum. In our study, patients had pericardiocentesis
within aweek of starting anti-TB therapy. Thus, the initial bacterial bur-
den may actually be falsely lower in some patients because of effects of
therapy. However, the caveat is that these were patients chosen based
on the basis of a positive Mtb culture in pericardial ﬂuid, which could
skew the bacterial burden.
The third important ﬁnding was that the bacillary load was a signif-
icant predictor for both early and late mortality outcomes. This aspect
outranked well-known hemodynamic predictors of mortality in TB
pericarditis such as hypotension. Moreover, this even outranked type
of pericardial syndromes such as constrictive pericarditis versus effusive
pericarditis versus effusive–constrictive disease. Thus, in prioritizing
decisions to decrease the highmortality, a priority should be to ﬁnd rap-
idly bactericidal drugs, or even exploration of the notion of decreasing
the large bacterial burden via drainage (i.e., draining the cold abscess-
es). It is a well-known principle of antimicrobial PK/PD science, and
indeed of standard microbiology, that the higher the bacterial burden,
the greater the chances of treatment failure and development of
acquired drug resistance (Gumbo et al., 2015; Jumbe et al., 2003;Fig. 4. Survival in patients with CART identiﬁed predictors of highmortality Patients with
bacterial burden of N553 log10CFU experienced signiﬁcantly higher overall mortality and
higher hazards over the entire follow-up. The hazard rate was 2.86 (95% CI 1.01, 7.69),
p = 0·044. The vertical line indicates the 5.23 months follow-up time point identiﬁed
by classiﬁcation and regression tree (CART) analysis.Gumbo, 2011). Indeed, for some patients, the initial bacillary burden
was above the inverse of the mutation frequency of 10−7 of the only
effective antibiotic that penetrates well into pericardial ﬂuid: isoniazid
(Shenje et al., 2015). This means that acquired resistance due to effec-
tivemonotherapy could be a problemat these high pericardialﬂuid bac-
terial burdens. Moreover, time to total sterilization of bacteria in higher
bacterial burden disease will be longer than with smaller bacterial bur-
dens, given that dose–response curves of antibiotics reveal a ceiling kill-
ing rate. Thus, time to cure is longerwith high burden disease, especially
given the limited number of drugs in the standard regimen that pene-
trate into pericardium(Shenje et al., 2015).
There are limitations to these data. First, we only examined proven
TB pericarditis and excluded suspected pericarditis. This criterion
might have biased against suspected TB pericarditis patients with such
low bacillary burden that cultures fail to grow: a phenomenon also
encountered with culture negative pulmonary TB. Nevertheless, our
comparison was with culture positive pulmonary TB, a disease univer-
sally considered multi-bacillary. The second limitation is that CART
identiﬁes predictors, but does not assign a causal pathway. Our ﬁndings
thus constitute a hypothesis, which should be tested in a large prospec-
tive dataset. Second longer follow-up and data may be required to
delineate effects of TB/HIV related cardiomyopathy as well as the effect
of sustained antiretroviral therapy. Data of antiretroviral therapy were
available in 44/70 (63%) of patients and only 8/47 (17%) of known HIV
positive patients were on therapy. The low % of patients on antiretrovi-
ral drugs is because the study recruitmentwas during a periodwhen the
timing of initiation of antiretroviral therapy in patients with tuberculo-
sis was still being studied, and also occurred during the early rollout
period for antiretroviral drugs.Author Contributions
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